Rituximab in Membranous Nephropathy

Philipp Gauckler; Jae Il Shin; Federico Alberici; RITERM study group; Vincent Audard; Annette Bruchfeld; Martin Busch; Chee Kay Cheung; Matija Crnogorac; Elisa Delbarba; Kathrin Eller; Stanislas Faguer; Kresimir Galesic; Siân Griffin; Martijn W.F. van den Hoogen; Zdenka Hrušková; Anushya Jeyabalan; Alexandre Karras; Catherine King; Harbir Singh Kohli; Gert Mayer; Rutger Maas; Masahiro Muto; Sergey Moiseev; Balazs Odler; Ruth J. Pepper; Luis F. Quintana; Jai Radhakrishnan; Raja Ramachandran; Alan D. Salama; Ulf Schönermarck; Mårten Segelmark; Lee Smith; Vladimír Tesař; Jack Wetzels; Lisa Willcocks; Martin Windpessl; Ladan Zand; Reza Zonozi; Andreas Kronbichler

doi:10.1016/j.ekir.2020.12.035

Rituximab in Membranous Nephropathy

Philipp Gauckler^*, Jae Il Shin, Federico Alberici, RITERM study group, Vincent Audard, Annette Bruchfeld, Martin Busch, Chee Kay Cheung, Matija Crnogorac, Elisa Delbarba, Kathrin Eller, Stanislas Faguer, Kresimir Galesic, Siân Griffin, Martijn W.F. van den Hoogen, Zdenka Hrušková, Anushya Jeyabalan, Alexandre Karras, Catherine King, Harbir Singh KohliGert Mayer, Rutger Maas, Masahiro Muto, Sergey Moiseev, Balazs Odler, Ruth J. Pepper, Luis F. Quintana, Jai Radhakrishnan, Raja Ramachandran, Alan D. Salama, Ulf Schönermarck, Mårten Segelmark, Lee Smith, Vladimír Tesař, Jack Wetzels, Lisa Willcocks, Martin Windpessl, Ladan Zand, Reza Zonozi, Andreas Kronbichler

^*Corresponding author for this work

Internal Medicine

Research output: Contribution to journal › Review article › Academic › peer-review

39 Citations (Scopus)

46 Downloads (Pure)

Abstract

Membranous nephropathy (MN) is the most common cause of primary nephrotic syndrome among adults. The identification of phospholipase A2 receptor (PLA2R) as target antigen in most patients changed the management of MN dramatically, and provided a rationale for B-cell depleting agents such as rituximab. The efficacy of rituximab in inducing remission has been investigated in several studies, including 3 randomized controlled trials, in which complete and partial remission of proteinuria was achieved in approximately two-thirds of treated patients. Due to its favorable safety profile, rituximab is now considered a first-line treatment option for MN, especially in patients at moderate and high risk of deterioration in kidney function. However, questions remain about how to best use rituximab, including the optimal dosing regimen, a potential need for maintenance therapy, and assessment of long-term safety and efficacy outcomes. In this review, we provide an overview of the current literature and discuss both strengths and limitations of “the new standard.”

Original language	English
Pages (from-to)	881-893
Number of pages	13
Journal	Kidney International Reports
Volume	6
Issue number	4
DOIs	https://doi.org/10.1016/j.ekir.2020.12.035
Publication status	Published - 1 Apr 2021

Bibliographical note

Access to Document

10.1016/j.ekir.2020.12.035

PIIS2468024920318696Final published version, 625 KBLicence: CC BY-NC-ND

Cite this

Gauckler, P., Shin, J. I., Alberici, F., RITERM study group, Audard, V., Bruchfeld, A., Busch, M., Cheung, C. K., Crnogorac, M., Delbarba, E., Eller, K., Faguer, S., Galesic, K., Griffin, S., van den Hoogen, M. W. F., Hrušková, Z., Jeyabalan, A., Karras, A., King, C., ... Kronbichler, A. (2021). Rituximab in Membranous Nephropathy. Kidney International Reports, 6(4), 881-893. https://doi.org/10.1016/j.ekir.2020.12.035

@article{5bd83f609cb34cb4af39331a3559c2b6,

title = "Rituximab in Membranous Nephropathy",

abstract = "Membranous nephropathy (MN) is the most common cause of primary nephrotic syndrome among adults. The identification of phospholipase A2 receptor (PLA2R) as target antigen in most patients changed the management of MN dramatically, and provided a rationale for B-cell depleting agents such as rituximab. The efficacy of rituximab in inducing remission has been investigated in several studies, including 3 randomized controlled trials, in which complete and partial remission of proteinuria was achieved in approximately two-thirds of treated patients. Due to its favorable safety profile, rituximab is now considered a first-line treatment option for MN, especially in patients at moderate and high risk of deterioration in kidney function. However, questions remain about how to best use rituximab, including the optimal dosing regimen, a potential need for maintenance therapy, and assessment of long-term safety and efficacy outcomes. In this review, we provide an overview of the current literature and discuss both strengths and limitations of “the new standard.”",

author = "Philipp Gauckler and Shin, {Jae Il} and Federico Alberici and {RITERM study group} and Vincent Audard and Annette Bruchfeld and Martin Busch and Cheung, {Chee Kay} and Matija Crnogorac and Elisa Delbarba and Kathrin Eller and Stanislas Faguer and Kresimir Galesic and Si{\^a}n Griffin and {van den Hoogen}, {Martijn W.F.} and Zdenka Hru{\v s}kov{\'a} and Anushya Jeyabalan and Alexandre Karras and Catherine King and Kohli, {Harbir Singh} and Gert Mayer and Rutger Maas and Masahiro Muto and Sergey Moiseev and Balazs Odler and Pepper, {Ruth J.} and Quintana, {Luis F.} and Jai Radhakrishnan and Raja Ramachandran and Salama, {Alan D.} and Ulf Sch{\"o}nermarck and M{\aa}rten Segelmark and Lee Smith and Vladim{\'i}r Tesa{\v r} and Jack Wetzels and Lisa Willcocks and Martin Windpessl and Ladan Zand and Reza Zonozi and Andreas Kronbichler",

note = "Publisher Copyright: {\textcopyright} 2021",

year = "2021",

month = apr,

day = "1",

doi = "10.1016/j.ekir.2020.12.035",

language = "English",

volume = "6",

pages = "881--893",

journal = "Kidney International Reports",

issn = "2468-0249",

publisher = "Elsevier Inc.",

number = "4",

}

Gauckler, P, Shin, JI, Alberici, F, RITERM study group, Audard, V, Bruchfeld, A, Busch, M, Cheung, CK, Crnogorac, M, Delbarba, E, Eller, K, Faguer, S, Galesic, K, Griffin, S, van den Hoogen, MWF, Hrušková, Z, Jeyabalan, A, Karras, A, King, C, Kohli, HS, Mayer, G, Maas, R, Muto, M, Moiseev, S, Odler, B, Pepper, RJ, Quintana, LF, Radhakrishnan, J, Ramachandran, R, Salama, AD, Schönermarck, U, Segelmark, M, Smith, L, Tesař, V, Wetzels, J, Willcocks, L, Windpessl, M, Zand, L, Zonozi, R & Kronbichler, A 2021, 'Rituximab in Membranous Nephropathy', Kidney International Reports, vol. 6, no. 4, pp. 881-893. https://doi.org/10.1016/j.ekir.2020.12.035

TY - JOUR

T1 - Rituximab in Membranous Nephropathy

AU - Gauckler, Philipp

AU - Shin, Jae Il

AU - Alberici, Federico

AU - RITERM study group

AU - Audard, Vincent

AU - Bruchfeld, Annette

AU - Busch, Martin

AU - Cheung, Chee Kay

AU - Crnogorac, Matija

AU - Delbarba, Elisa

AU - Eller, Kathrin

AU - Faguer, Stanislas

AU - Galesic, Kresimir

AU - Griffin, Siân

AU - van den Hoogen, Martijn W.F.

AU - Hrušková, Zdenka

AU - Jeyabalan, Anushya

AU - Karras, Alexandre

AU - King, Catherine

AU - Kohli, Harbir Singh

AU - Mayer, Gert

AU - Maas, Rutger

AU - Muto, Masahiro

AU - Moiseev, Sergey

AU - Odler, Balazs

AU - Pepper, Ruth J.

AU - Quintana, Luis F.

AU - Radhakrishnan, Jai

AU - Ramachandran, Raja

AU - Salama, Alan D.

AU - Schönermarck, Ulf

AU - Segelmark, Mårten

AU - Smith, Lee

AU - Tesař, Vladimír

AU - Wetzels, Jack

AU - Willcocks, Lisa

AU - Windpessl, Martin

AU - Zand, Ladan

AU - Zonozi, Reza

AU - Kronbichler, Andreas

PY - 2021/4/1

Y1 - 2021/4/1

N2 - Membranous nephropathy (MN) is the most common cause of primary nephrotic syndrome among adults. The identification of phospholipase A2 receptor (PLA2R) as target antigen in most patients changed the management of MN dramatically, and provided a rationale for B-cell depleting agents such as rituximab. The efficacy of rituximab in inducing remission has been investigated in several studies, including 3 randomized controlled trials, in which complete and partial remission of proteinuria was achieved in approximately two-thirds of treated patients. Due to its favorable safety profile, rituximab is now considered a first-line treatment option for MN, especially in patients at moderate and high risk of deterioration in kidney function. However, questions remain about how to best use rituximab, including the optimal dosing regimen, a potential need for maintenance therapy, and assessment of long-term safety and efficacy outcomes. In this review, we provide an overview of the current literature and discuss both strengths and limitations of “the new standard.”

AB - Membranous nephropathy (MN) is the most common cause of primary nephrotic syndrome among adults. The identification of phospholipase A2 receptor (PLA2R) as target antigen in most patients changed the management of MN dramatically, and provided a rationale for B-cell depleting agents such as rituximab. The efficacy of rituximab in inducing remission has been investigated in several studies, including 3 randomized controlled trials, in which complete and partial remission of proteinuria was achieved in approximately two-thirds of treated patients. Due to its favorable safety profile, rituximab is now considered a first-line treatment option for MN, especially in patients at moderate and high risk of deterioration in kidney function. However, questions remain about how to best use rituximab, including the optimal dosing regimen, a potential need for maintenance therapy, and assessment of long-term safety and efficacy outcomes. In this review, we provide an overview of the current literature and discuss both strengths and limitations of “the new standard.”

UR - http://www.scopus.com/inward/record.url?scp=85102860879&partnerID=8YFLogxK

U2 - 10.1016/j.ekir.2020.12.035

DO - 10.1016/j.ekir.2020.12.035

M3 - Review article

AN - SCOPUS:85102860879

SN - 2468-0249

VL - 6

SP - 881

EP - 893

JO - Kidney International Reports

JF - Kidney International Reports

IS - 4

ER -

Rituximab in Membranous Nephropathy

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this